An international collaboration led by Prof. Lih-Chu Chiou, College of Medicine, National Taiwan University, has identified a novel promising drug candidate, the α6-containing GABAA receptor-selective positive allosteric modulator, for the treatment of migraine, trigeminal painneuropsychiatric disorders (schizophreniaTourette syndrome).